FDA approves Gilead's Hepcludex as the first treatment for chronic hepatitis delta
The first-in-class entry inhibitor cleared a 48%-versus-2% Week 48 virologic and biochemical response — reaching US patients three years after the FDA turned down the original 2 mg dose.